# Clinical Trials Data EGFR - Document 16

# The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

## Clinical Trial: https://clinicaltrials.gov/study/NCT01608841

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic chemotherapy-na\u00efve pancreatic cancer patients\n\* histologically confirmed\n\* adequate samples for analysis\n\* Eastern Cooperative Oncology Group (ECOG) performance status \\<= 2\n\* absolute neutrophil count (ANC) \\>= 1,500/mm3\n\* platelet count \\>= 100,000/mm3\n\* serum creatinine \\<= 1.5 mg/dL\n\* aspartate aminotransferase (AST)\n\* alanine aminotransferase (ALT) \\< 5 times the upper limit of normal\n\nExclusion Criteria:\n\n\* absence of any other malignancy or serious medical or psychological illness that would preclude informed consent",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
The provided information doesn't mention EGFR mutations as either an inclusion or exclusion criterion. Therefore, having an EGFR mutation \*doesn't automatically disqualify\* a patient. They would need to meet all other inclusion criteria and not meet any exclusion criteria to be eligible.